CDK4 and B-cell non-Hodgkin lymphoma: Noteworthy findings included the high activity of CDK6 substrates in the Pfeiffer cell line, a diffuse large B-cell lymphoma line, aligning with reports that CDK4/6 inhibitors are effective against aggressive B-cell lymphomas.48